Entrada Therapeutics Inc (TRDA) Stock Price, Quote & News

Company Profile

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 520 9158

Website: www.entradatx.com

Address:

One Design Center Place, Suite 17- 500, Boston, United States

outlawinvestor1 Jul. 26 at 1:49 PM

$TRDA I’ve started a position at these levels. Clinical stage biotech with minimal spend, partnership and licensing revenues from a strong rare disease biotech player trading below cash. Another potential headwind that seems to have missed entrada so far is that they’re delivering a gene therapy without the potential/perceived harm of AAV viral vectors (eg $SRPT). Will buy/build more, if it dips further. My only critique is that they don’t give guidance on future trial readouts in their corporate pdf so not sure when the catalyst events will take place.

0 · Reply

Tradr1205 Jul. 15 at 4:45 PM

$TRDA Bought some more. This is over-blown. Reversal forthcoming

2 · Reply

VinWeezel Jul. 15 at 3:59 PM

$TRDA prolly more 5am ventures selling-Market selling tiny bits into 0 volume. Downward pressure. Not ideal days here.

2 · Reply

Tradr1205 Jul. 11 at 6:01 AM

$TRDA Bought a nice chunck before the market closed. I think we're trading back above $7 in the am

0 · Reply

Goosem4n Jul. 10 at 5:48 PM

$TRDA anyone shorting this hasn't checked the balance sheet.

1 · Reply

VinWeezel Jul. 10 at 12:24 AM

$TRDA anyone here at all? Turda rockets or no?

1 · Reply

VinWeezel Jun. 27 at 8:33 PM

$TRDA 400,000 shares traded ah and no price movement

0 · Reply

VinWeezel Jun. 25 at 4:46 PM

$TRDA https://www.tradingview.com/news/tradingview:da469c2620fe4:0-entrada-therapeutics-director-kim-peter-s-acquires-25-000-shares/ this was repoted again last week cause he filed wrong. He bought 25,000 two days in a row. But how did he pay 14 in may when price was 9? This guy is literally a genius. I’m adding.

1 · Reply

valueforme Jun. 17 at 1:19 AM

$TRDA Forgotten stock. Depending on what DYN has to say tomorrow, I might consider buying here

1 · Reply

VinWeezel May. 28 at 5:54 PM

$TRDA https://www.stocktitan.net/news/TRDA/entrada-therapeutics-receives-authorization-in-the-european-union-to-oko6tip1t5oz.html

0 · Reply

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

BIIB

Jun 2, 2025, 4:30 PM EDT - 7 weeks ago

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 28, 2025, 7:00 AM EDT - 2 months ago

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 8, 2025, 7:00 AM EDT - 2 months ago

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Mar 24, 2025, 7:00 AM EDT - 4 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Feb 27, 2025, 7:00 AM EST - 5 months ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 7:00 AM EST - 5 months ago

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Feb 19, 2025, 11:31 AM EST - 5 months ago

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Feb 3, 2025, 7:00 AM EST - 6 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Jan 30, 2025, 4:05 PM EST - 6 months ago

Azenta Announces the Election of Dipal Doshi to its Board of Directors

AZTA

Dec 18, 2024, 7:00 AM EST - 7 months ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Oct 9, 2024, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Sep 24, 2024, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Sep 17, 2024, 8:30 AM EDT - 11 months ago

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Sep 6, 2024, 7:00 AM EDT - 11 months ago

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Jun 24, 2024, 7:15 AM EDT - 1 year ago

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Jun 24, 2024, 6:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 16, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 7, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 7, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

Nov 22, 2023, 7:00 AM EST - 1 year ago

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Aug 8, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 6:39 PM EDT - 2 years ago

Entrada Therapeutics: Early Stage But Interesting

Jun 6, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 10, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports First Quarter 2023 Financial Results

Apr 4, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Mar 29, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Mar 6, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 27, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Dec 19, 2022, 4:30 PM EST - 2 years ago

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Dec 8, 2022, 8:24 AM EST - 2 years ago

Entrada Therapeutics shares jump on collaboration with Vertex

Dec 8, 2022, 7:00 AM EST - 2 years ago

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

VRTX

Nov 7, 2022, 7:00 AM EST - 2 years ago

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Aug 30, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

Jul 19, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

Jul 6, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

Jun 1, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

May 12, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports First Quarter 2022 Financial Results

May 11, 2022, 9:30 AM EDT - 3 years ago

Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022

Apr 18, 2022, 9:48 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch: Aterian And Newegg Remain In Top Two Positions, Cannabis Company Joins List Week Of 4/20

ATER NEGG BEEM

Mar 15, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Feb 23, 2022, 8:00 AM EST - 3 years ago

Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

outlawinvestor1 Jul. 26 at 1:49 PM

0 · Reply

Tradr1205 Jul. 15 at 4:45 PM

$TRDA Bought some more. This is over-blown. Reversal forthcoming

2 · Reply

VinWeezel Jul. 15 at 3:59 PM

$TRDA prolly more 5am ventures selling-Market selling tiny bits into 0 volume. Downward pressure. Not ideal days here.

2 · Reply

Tradr1205 Jul. 11 at 6:01 AM

$TRDA Bought a nice chunck before the market closed. I think we're trading back above $7 in the am

0 · Reply

Goosem4n Jul. 10 at 5:48 PM

$TRDA anyone shorting this hasn't checked the balance sheet.

1 · Reply

VinWeezel Jul. 10 at 12:24 AM

$TRDA anyone here at all? Turda rockets or no?

1 · Reply

VinWeezel Jun. 27 at 8:33 PM

$TRDA 400,000 shares traded ah and no price movement

0 · Reply

VinWeezel Jun. 25 at 4:46 PM

1 · Reply

valueforme Jun. 17 at 1:19 AM

$TRDA Forgotten stock. Depending on what DYN has to say tomorrow, I might consider buying here

1 · Reply

VinWeezel May. 28 at 5:54 PM

$TRDA https://www.stocktitan.net/news/TRDA/entrada-therapeutics-receives-authorization-in-the-european-union-to-oko6tip1t5oz.html

0 · Reply

VinWeezel May. 25 at 3:42 PM

$TRDA 16 this shortened week

0 · Reply

xrichsayzx88 May. 20 at 6:33 PM

$TRDA $10

0 · Reply

JarvisFlow May. 20 at 11:00 AM

HC Wainwright & Co. updates rating for Entrada Therapeutics ( $TRDA ) to Buy, target set at 20.

0 · Reply

VinWeezel May. 18 at 11:54 AM

$TRDA lets go to 16 this week 😬

0 · Reply

Uneducated_Trader May. 15 at 1:46 PM

$TRDA

0 · Reply

Armonica423 May. 10 at 5:20 PM

$TRDA Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

Thestocktraderhubzee May. 8 at 11:17 AM

$TRDA Entrada Therapeutics Q1 EPS $(0.42) Beats $(0.76) Estimate, Sales $20.56M Beat $10.17M Estimate

0 · Reply

maizeblue22 Apr. 4 at 2:50 PM

$TRDA promising skeleton key-like tech, beat up by a red market. This is a steal at this SP

0 · Reply

Avocado_smash Apr. 1 at 4:21 PM

$TRDA 👇

0 · Reply

JarvisFlow Mar. 31 at 11:30 AM

HC Wainwright & Co. updates rating for Entrada Therapeutics ( $TRDA ) to Buy, target set at 20.

0 · Reply

Avocado_smash Mar. 30 at 4:14 PM

$TRDA PT 9.35 and lower low.

0 · Reply

TwongStocks Mar. 17 at 2:45 PM

$CAPR $TRDA Both companies will take part in a panel at the Roth Annual Conference today. <<Opportunities and Challenges in Duchenne Muscular Dystrophy>> 12:00pm ET/9:00am PT https://wsw.com/webcast/roth50/

1 · Reply

Market Cap	242.52M
Revenue (ttm)	210.78M
Net Income (ttm)	65.63M
EPS (ttm)	N/A
PE Ratio	7.89
Forward PE	N/A
Profit Margin	31.14%
Debt to Equity Ratio	0.00

Volume	120,800
Avg Vol	138,330
Day's Range	N/A - N/A
Shares Out	37.95M
Stochastic %K	54%
Beta	-0.11
Analysts	Strong Sell
Price Target	$20.50